|
|
Post by mytakeonit on Apr 11, 2023 12:54:28 GMT -5
Seems that if we are headed for quarterly payments ... that you would want to increase your share holdings and not just sit on the few.
But, that's mytakeonit
|
|
|
|
Post by cretin11 on Apr 11, 2023 13:23:10 GMT -5
MTOI, I almost included one of your trademark sayings, “buy all the cheap shares you can!”
But what do you mean by “headed for quarterly payments”?
|
|
|
|
Post by mytakeonit on Apr 11, 2023 13:33:05 GMT -5
If / When MNKD starts receiving royalty payments quarterly ... it is normal for the company to pass some on to shareholders at some point.
But, that's mytakeonit
|
|
|
|
Post by JEvans on Apr 11, 2023 13:52:46 GMT -5
If / When MNKD starts receiving royalty payments quarterly ... it is normal for the company to pass some on to shareholders at some point. But, that's mytakeonit I don't believe thats how it works my friend ! Either the stock pays dividends or it doesn't. But you would think PPS would go up.... |
|
|
|
Post by awesomo on Apr 11, 2023 13:58:32 GMT -5
If / When MNKD starts receiving royalty payments quarterly ... it is normal for the company to pass some on to shareholders at some point. But, that's mytakeonit Companies that are unprofitable don't issue regular dividends. Also companies that are in a growth phase don't issue dividends as profits get put back into the company to fuel that growth. |
|
|
|
Post by mytakeonit on Apr 11, 2023 13:58:33 GMT -5
If we start receiving dividend payments ... MNKD share price will climb. But in this case I feel that the share price will climb first ... with dividends to follow later.
But, that's mytakeonit
And to awesomo ... we are currently headed to cash flow break even.
|
|
|
|
Post by prcgorman2 on Apr 11, 2023 14:01:03 GMT -5
All these posts urging awesomo to sell were so persuasive, I was about to pull the trigger but gorman you talked me off the ledge. Not epic (so we can’t accuse you of exaggerating) but “almost miraculous” that we are here, plus “pretty remarkable” Afrezza script growth at 800 TRx in year nine. I guess if we can keep saying “30% year over year” that is comforting. All this and we can still buy shares under $0.80 RS adjusted. Heck no I’m not selling! Talked you off the ledge? I assure you, I wasn't trying to talk anyone off a ledge. Besides how much would you lose? You've had plenty of time to average down after the RS that happened several years ago under previous management. Many report being in the green even at only $4/share. And I didn't urge awesomo to sell. What I said was I couldn't hate a company and also still own shares in it, and I admired his "patience". When I owned shares in a company I came to hate, I sold, and reinvested elsewhere, and much the happier for it. I'm not urging you to sell either. Stay on the ledge. But if you do choose to sell all or a portion of your shares, I hope it brings you some relief. |
|
|
|
Post by awesomo on Apr 11, 2023 14:08:39 GMT -5
I'd like to know where your claim that Mike said Afrezza is "already break-even" came from prcgorman2 . Seems like a pretty important thing to highlight that I would be happy to acknowledge. Or just say that you spread misinformation. |
|
|
|
Post by hopingandwilling on Apr 11, 2023 14:50:27 GMT -5
PRC,
I'm intrigued by your claim that MNKD is growing weekly scrips by running about 30% growth. And yet there are those of you who claim that Sanofi dumped Afrezza back into MNKD's lap to market Afrezza. How quickly you forget that the current CEO was hired by MannKind, he boasted that he was going to show Sanofi how to market Afrezza and he would do it with less money than what Sanofi was spending.
So let's look at the last seven weeks data for the current NRxs that your CEO is producing--over these seven weeks, there has been one week that broke the 400 level. The other six weeks are in the 300s. Now go back to when Sanofi launched Afrezza and there was not one doctor who had ever issued a script for Afrezza--it was an all-virgin marketplace for Afrezza. Yet within 18 weeks Sanofi's NRxs broke the 300 market and eventual topped the 400 level and they made a decision---there is no market for this product--and they cut their losses. Dr. Mike took over and low and behold after several years of his boasting about his market acumen, he is generating NRx in the 300 level and you claim Afrezza is growing by 30%. Do you realize that so far in 2023, the weekly sequential growth in NRxs is down more than being up on a weekly sequential basis? Then only growth that has occurred, under the current CEO, is his yearly compensation being over $1 million bucks-----and he claims how he was going to show Sanofi up and do it cheaper. Now nine years after Afrezza was approved by the FDA, Sanofi signed on, MannKind got a partnership (only the second one in their history) with United for Tyvaso DPI, and in these last nine years, the stock is currently selling for what is equivalent to being less than $0.80 when you consider the 1:5 reverse split. Yep! Things are booming for MannKind---Keep your dreaming alive!
|
|
|
|
Post by mytakeonit on Apr 11, 2023 14:53:35 GMT -5
MNKD shareholder meeting is set for May 25th ... make your vote count by May 24th.
But, that's mytakeonit
BTW, isn't it interesting that today's posts seem to have brought out the obvious shorts ... like a lightbulb brings out termites.
|
|
|
|
Post by prcgorman2 on Apr 11, 2023 15:42:40 GMT -5
I'd like to know where your claim that Mike said Afrezza is "already break-even" came from prcgorman2 . Seems like a pretty important thing to highlight that I would be happy to acknowledge. Or just say that you spread misinformation. I skipped looking at your link to a transcript on MF given the whole "rest and grow" misinformation fiasco from a bad transcript.
Instead I listened to the earnings call (which before I had just read a transcript). I recall that Mike's statement was regarding "the board" (of directors) providing guidance on the Endocrine Business Unit (EBU) having a goal of needing to be profitable by year end and that Mike said "Afrezza was already profitable" (or words to that effect), and I might have missed it in the Q4 earnings report (I was multitasking) but I think now it must've been either the SVB or other conference from this year. I'll go check those and if someone else remembers sooner and can provide a pointer that will be appreciated.
|
|
|
|
Post by prcgorman2 on Apr 11, 2023 15:43:57 GMT -5
PRC, I'm intrigued by your claim that MNKD is growing weekly scrips by running about 30% growth. And yet there are those of you who claim that Sanofi dumped Afrezza back into MNKD's lap to market Afrezza. How quickly you forget that the current CEO was hired by MannKind, he boasted that he was going to show Sanofi how to market Afrezza and he would do it with less money than what Sanofi was spending. So let's look at the last seven weeks data for the current NRxs that your CEO is producing--over these seven weeks, there has been one week that broke the 400 level. The other six weeks are in the 300s. Now go back to when Sanofi launched Afrezza and there was not one doctor who had ever issued a script for Afrezza--it was an all-virgin marketplace for Afrezza. Yet within 18 weeks Sanofi's NRxs broke the 300 market and eventual topped the 400 level and they made a decision---there is no market for this product--and they cut their losses. Dr. Mike took over and low and behold after several years of his boasting about his market acumen, he is generating NRx in the 300 level and you claim Afrezza is growing by 30%. Do you realize that so far in 2023, the weekly sequential growth in NRxs is down more than being up on a weekly sequential basis? Then only growth that has occurred, under the current CEO, is his yearly compensation being over $1 million bucks-----and he claims how he was going to show Sanofi up and do it cheaper. Now nine years after Afrezza was approved by the FDA, Sanofi signed on, MannKind got a partnership (only the second one in their history) with United for Tyvaso DPI, and in these last nine years, the stock is currently selling for what is equivalent to being less than $0.80 when you consider the 1:5 reverse split. Yep! Things are booming for MannKind---Keep your dreaming alive! Sorry hoping. TL;DR. |
|
|
|
Post by cretin11 on Apr 11, 2023 15:56:58 GMT -5
Definitely should vote, but I wish there were actually a way to “make it count.”
I haven’t noticed any shorts here, been looking for them in vain!
|
|
|
|
Post by prcgorman2 on Apr 11, 2023 16:09:58 GMT -5
Definitely should vote, but I wish there were actually a way to “make it count.” I haven’t noticed any shorts here, been looking for them in vain! It counts, but if you really want it to count, you'll need to buy more shares. A lot more.  |
|
|
|
Post by sportsrancho on Apr 11, 2023 16:14:32 GMT -5
MNKD shareholder meeting is set for May 25th ... make your vote count by May 24th. But, that's mytakeonit BTW, isn't it interesting that today's posts seem to have brought out the obvious shorts ... like a lightbulb brings out termites. It's like politics, the pendulum swings back and forth, depending on the climate.😓 |
|
